Ingenuity Health Study Reveals Potential Non-Adherence to Antipsychotic Medications Differs Based on Diagnosis

June 24, 2015

Will Present Clinical Research to Psychopharmacology Community


BALTIMORE – June 24, 2015 – Ameritox’s Ingenuity Health, a leading provider of medication monitoring solutions to behavioral health clinicians, today announced new clinical research based on urine drug monitoring samples that revealed that participants who suffer from bipolar disorder and severe depression are more likely to be non-adherent to their prescribed antipsychotic medication than those who suffer from schizophrenia. These results differ from recent literature on non-adherence in those with serious mental illness (SMI).

Medication nonadherence can result in significant barriers to the long-term health of those with SMI.

“This research challenges current notions about medication adherence among those with bipolar disorder and severe depression, but it remains clear that non-adherence is the single greatest threat to long-term health for those who suffer from SMI,” said Tom Smith, M.D., Chief Medical Officer for Ingenuity Health and Ameritox.

Ingenuity Health medical scientists, along with research contributor Dr. Robert Millet, Assistant Medical Director of Carolina Behavioral Care in Raleigh, NC, will present the research in a medical poster titled “Adherence to Treatment With Antipsychotic Medications Among Patients With Schizophrenia, Major Depressive Disorder, or Bipolar Disorder” today at the annual meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, Fla.

“Simply put, this study shows that we need more vigilance of medications among the seriously mentally ill, especially considering that medication monitoring is the easiest way to improve patient outcomes,” said Dr. Millet. “Although it’s widely accepted that patients with schizophrenia would benefit from medication monitoring, this dataset suggests that patients with bipolar disorder and depression should also be monitored.”

Additionally, Ingenuity Health will present at the ASCP annual meeting a medical poster titled “Evaluation of Cytochrome P450 Phenotypes and Potential Implications in the Treatment of Serious Mental Illness.”

For more information about ASCP and its annual meeting, visit https://www.ascpp.org.

About Ingenuity Health
As part of Ameritox, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with serious mental illness (SMI).

Visit the Ingenuity Health website at: www.ingenuityhealth.com
Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Contact: Lon Wagner
Director of Communications, Ameritox
(336) 387-7742
lon.wagner@ameritox.com

Genevieve Rozansky
202-509-0794
genevieve@30point.com